Literature DB >> 7945266

Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor.

C Boudier1, J G Bieth.   

Abstract

N-chlorosuccinimide oxidizes one of the methionine residues of mucus proteinase inhibitor with a second-order rate constant of 1.5 M-1.s-1. Cyanogen bromide cleavage and NH2-terminal sequencing show that the modified residue is methionine-73, the P'1 component of the inhibitor's active centre. Oxidation of the inhibitor decreases its neutrophil elastase inhibitory capacity but does not fully abolish it. The kinetic parameters describing the elastase-oxidized inhibitor interaction are: association rate constant kass. = 2.6 x 10(5) M-1.s-1, dissociation rate constant kdiss. = 2.9 x 10(-3) s-1 and equilibrium dissociation constant Ki = 1.1 x 10(-8) M. Comparison with the native inhibitor indicates that oxidation decreases kass. by a factor of 18.8 and increases kdiss. by a factor of 6.4, and therefore leads to a 120-fold increase in Ki. Yet, the oxidized inhibitor may still act as a potent elastase inhibitor in the upper respiratory tract where its concentration is 500-fold higher than Ki, i.e. where the elastase inhibition is pseudo-irreversible. Experiments in vitro with fibrous human lung elastin, the most important natural substrate of elastase, support this view: 1.35 microM elastase is fully inhibited by 5-6 microM oxidized inhibitor whether the enzyme-inhibitor complex is formed in the presence or absence of elastin and whether elastase is pre-adsorbed on elastin or not.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945266      PMCID: PMC1137557          DOI: 10.1042/bj3030061

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  Location of the protease-inhibitory region of secretory leukocyte protease inhibitor.

Authors:  S P Eisenberg; K K Hale; P Heimdal; R C Thompson
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

2.  Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.

Authors:  C Vogelmeier; R C Hubbard; G A Fells; H P Schnebli; R C Thompson; H Fritz; R G Crystal
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

3.  Interaction of human alpha-1-proteinase inhibitor with neutrophil myeloperoxidase.

Authors:  N R Matheson; P S Wong; M Schuyler; J Travis
Journal:  Biochemistry       Date:  1981-01-20       Impact factor: 3.162

4.  Purification of a serine-proteinase inhibitor from human articular cartilage. Identity with the acid-stable proteinase inhibitor of mucous secretions.

Authors:  B Böhm; R Deutzmann; H Burkhardt
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

5.  Effect of human antileucoprotease on experimental emphysema.

Authors:  A Rudolphus; J A Kramps; J H Dijkman
Journal:  Eur Respir J       Date:  1991-01       Impact factor: 16.671

6.  Stimulation of the elastolytic activity of leukocyte elastase by leukocyte cathepsin G.

Authors:  C Boudier; C Holle; J G Bieth
Journal:  J Biol Chem       Date:  1981-10-25       Impact factor: 5.157

7.  The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine.

Authors:  L Strandberg; D A Lawrence; L B Johansson; T Ny
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

8.  Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats.

Authors:  A Gast; W Anderson; A Probst; H Nick; R C Thompson; S P Eisenberg; H Schnebli
Journal:  Am Rev Respir Dis       Date:  1990-04

9.  Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor.

Authors:  W G Rice; S J Weiss
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

10.  Elastin decreases the efficiency of neutrophil elastase inhibitors.

Authors:  M Padrines; J G Bieth
Journal:  Am J Respir Cell Mol Biol       Date:  1991-02       Impact factor: 6.914

View more
  7 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases.

Authors:  Nicolas Guyot; Gudmundur Bergsson; Marcus W Butler; Catherine M Greene; Sinéad Weldon; Efrat Kessler; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Biol Chem       Date:  2010-06       Impact factor: 3.915

Review 3.  Biochemistry and pathology of radical-mediated protein oxidation.

Authors:  R T Dean; S Fu; R Stocker; M J Davies
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

4.  Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury.

Authors:  Seisho Sakai; Hidehiro Tajima; Tomoharu Miyashita; Shin-Ichi Nakanuma; Isamu Makino; Hironori Hayashi; Hisatoshi Nakagawara; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Hidehito Saito; Seiichi Munesue; Yasuhiko Yamamoto; Tetsuo Ohta
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.199

Review 5.  Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.

Authors:  L Bingle; T D Tetley
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

6.  Reactive oxygen species regulate neutrophil recruitment and survival in pneumococcal pneumonia.

Authors:  Helen M Marriott; Laura E Jackson; Thomas S Wilkinson; A John Simpson; Tim J Mitchell; David J Buttle; Simon S Cross; Paul G Ince; Paul G Hellewell; Moira K B Whyte; David H Dockrell
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

Review 7.  Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment.

Authors:  Urszula Demkow; F J van Overveld
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.